Pramlintide

Generic Name: Pramlintide

Brand Names: Symlin

Drug Type: Small Molecule

Chemical Formula: C_₁₇₁H_₂₆₇N_₅₁O_₅₃S_₂

CAS Number: 151126-32-8

Unique Ingredient Identifier: D3FM8FA78T

Background: Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.

Indication: 用于1型和2型糖尿病的辅助治疗。

Associated Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

Clinical Trials

Tailoring Obesity Treatment Trial

Phase 2

Suspended

Conditions: Obesity
Appetite Regulation
PreDiabetes

Interventions: Drug: Semaglutide Pen Injector
Drug: Pramlintide Acetate 1 MG/ML
Drug: Sodium Chloride 0.9% Inj

First Posted Date: 2024-10-01

Last Posted Date: 2025-02-28

Lead Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark

Target Recruit Count: 40

Registration Number: NCT06619015

Locations: 🇩🇰
University hospital of Southern Denmark, Esbjerg, Denmark

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

Phase 2

Recruiting

Conditions: type1diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Pramlintide
Drug: Lyumjev
Device: Automated Insulin Delivery (AID) system

First Posted Date: 2023-09-21

Last Posted Date: 2024-04-18

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 30

Registration Number: NCT06046417

Locations: 🇨🇦
Research Institute of the McGill University Health Center, Montreal, Quebec, Canada

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Fiasp
Device: Artificial Pancreas
Drug: Pramlintide
Drug: Aspart

First Posted Date: 2022-01-20

Last Posted Date: 2023-10-25

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 12

Registration Number: NCT05199714

Locations: 🇨🇦
Research Institute of the McGill University Health Center, Montreal, Quebec, Canada

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Early Phase 1

Withdrawn

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Pramlintide

First Posted Date: 2020-02-05

Last Posted Date: 2023-06-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT04252612

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes

Not Applicable

Recruiting

Conditions: Type 1 Diabetes
Diabetes Mellitus, Type 1
Postprandial Hyperglycemia

Interventions: Drug: Rapid-Acting Insulin
Drug: Pramlintide Acetate
Drug: Placebo
Device: Artificial Pancreas

First Posted Date: 2020-01-28

Last Posted Date: 2023-03-15

Lead Sponsor: McGill University

Target Recruit Count: 26

Registration Number: NCT04243629

Locations: 🇨🇦
McGill University Health Centre, Montreal, Quebec, Canada

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus
Hyperglycemia, Postprandial
Type 1 Diabetes

Interventions: Drug: Fiasp
Drug: Placebo
Drug: Pramlintide Acetate
Device: Artificial Pancreas

First Posted Date: 2019-11-15

Last Posted Date: 2022-10-10

Lead Sponsor: McGill University

Target Recruit Count: 36

Registration Number: NCT04163874

Locations: 🇨🇦
3555 University Street, Montreal, Quebec, Canada

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1
Insulin-dependent Diabetes Mellitus

Interventions: Drug: PRAM9
Drug: Regular Insulin + Pramlintide
Drug: Regular Insulin

First Posted Date: 2019-08-30

Last Posted Date: 2024-03-27

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT04074317

Locations: 🇺🇸
World Wide Clinical Trials, San Antonio, Texas, United States

A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: ADO09 formulation
Drug: Symlin®
Drug: Placebo
Drug: Humulin®
Drug: Humalog®

First Posted Date: 2019-04-16

Last Posted Date: 2019-04-16

Lead Sponsor: Adocia

Target Recruit Count: 24

Registration Number: NCT03916640

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

Early Phase 1

Active, not recruiting

Conditions: Mild Cognitive Impairment
Alzheimer Disease

Interventions: Drug: Pramlintide challenge test

First Posted Date: 2018-06-19

Last Posted Date: 2025-04-04

Lead Sponsor: Boston University

Target Recruit Count: 57

Registration Number: NCT03560960

Locations: 🇺🇸
Indiana University Alzheimer Disease Center, Indianapolis, Indiana, United States
🇺🇸
BU Alzheimer Disease Center, Boston, Massachusetts, United States
🇺🇸
Memory Center VA Boston Healthcare, Jamaica Plain, Massachusetts, United States

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Humalog®
Drug: BC Pram Ins
Drug: Symlin® and Humulin®
Drug: Placebo

First Posted Date: 2018-04-30

Last Posted Date: 2019-02-21

Lead Sponsor: Adocia

Target Recruit Count: 24

Registration Number: NCT03512236

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy